Headlines about Glaukos (NYSE:GKOS) have been trending somewhat positive recently, Accern Sentiment reports. Accern scores the sentiment of media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Glaukos earned a media sentiment score of 0.21 on Accern’s scale. Accern also gave news articles about the medical instruments supplier an impact score of 45.9006638286013 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
GKOS has been the subject of several research analyst reports. Cantor Fitzgerald set a $48.00 price target on Glaukos and gave the stock a “buy” rating in a research note on Wednesday. BMO Capital Markets lowered their price target on Glaukos from $45.00 to $40.00 and set an “outperform” rating for the company in a research report on Wednesday, November 8th. BidaskClub lowered Glaukos from a “buy” rating to a “hold” rating in a research report on Monday, September 18th. Stephens reiterated a “buy” rating and set a $47.00 target price on shares of Glaukos in a report on Friday, September 15th. Finally, Zacks Investment Research upgraded Glaukos from a “sell” rating to a “hold” rating in a report on Monday, November 13th. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $44.86.
Shares of Glaukos (GKOS) opened at $28.56 on Friday. Glaukos has a 52 week low of $23.08 and a 52 week high of $52.49. The company has a market capitalization of $987.19 and a price-to-earnings ratio of -952.00.
Glaukos (NYSE:GKOS) last released its quarterly earnings results on Tuesday, November 7th. The medical instruments supplier reported $0.04 earnings per share for the quarter, beating the consensus estimate of ($0.02) by $0.06. The firm had revenue of $40.41 million for the quarter, compared to analysts’ expectations of $38.69 million. Glaukos had a return on equity of 4.12% and a net margin of 3.28%. The company’s revenue was up 36.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.03 EPS. analysts expect that Glaukos will post -0.03 EPS for the current year.
In related news, CFO Joseph E. Gilliam bought 2,100 shares of the firm’s stock in a transaction that occurred on Wednesday, November 22nd. The shares were bought at an average cost of $23.84 per share, with a total value of $50,064.00. Following the acquisition, the chief financial officer now owns 102,100 shares in the company, valued at $2,434,064. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 16.40% of the stock is currently owned by company insiders.
COPYRIGHT VIOLATION NOTICE: “Glaukos (GKOS) Given Daily News Impact Score of 0.21” was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international copyright laws. The correct version of this piece can be accessed at https://www.dispatchtribunal.com/2018/01/12/somewhat-positive-media-coverage-somewhat-unlikely-to-affect-glaukos-gkos-stock-price.html.
Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream.
Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.